ChemInform Abstract: Aleglitazar (I), a New, Potent, and Balanced Dual PPARα/γ Agonist for the Treatment of Type II Diabetes.

✍ Scribed by Peter Mohr; et al. et al.

• Publisher: John Wiley and Sons
• Year: 2009
• Weight: 13 KB
• Volume: 40
• Category: Article
• ISSN: 0931-7597
• DOI: 10.1002/chin.200936121